These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9510983)

  • 21. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys.
    Oikawa K; Kamimura H; Watanabe T; Miyamoto I; Higuchi S
    Thromb Res; 2001 Mar; 101(6):493-500. PubMed ID: 11323007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
    Agnelli G; Iorio A; Parise P; Goldhaber SZ; Levine MN
    Blood Coagul Fibrinolysis; 1997 Jun; 8(4):216-22. PubMed ID: 9199818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy.
    Bleich SD; Adgey AA; McMechan SR; Love TW
    Am Heart J; 1998 Oct; 136(4 Pt 1):741-8. PubMed ID: 9778080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration.
    Michels HR; Hoffman JJ; Bär FW
    J Thromb Thrombolysis; 1999 Oct; 8(3):213-21. PubMed ID: 10500311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
    Modi NB; Eppler S; Breed J; Cannon CP; Braunwald E; Love TW
    Thromb Haemost; 1998 Jan; 79(1):134-9. PubMed ID: 9459338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
    Gardell SJ; Ramjit DR; Stabilito II; Fujita T; Lynch JJ; Cuca GC; Jain D; Wang SP; Tung JS; Mark GE
    Circulation; 1991 Jul; 84(1):244-53. PubMed ID: 1905593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles.
    Modi NB; Reynolds T; Baughman SA; Thomas DA; Paasch BD; Smith SY
    J Cardiovasc Pharmacol; 1996 Jan; 27(1):105-12. PubMed ID: 8656642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats.
    Martin U; Sponer G; Strein K
    Drug Metab Dispos; 1993; 21(2):236-41. PubMed ID: 8097691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.
    Tanswell P; Tebbe U; Neuhaus KL; Gläsle-Schwarz L; Wojcik J; Seifried E
    J Am Coll Cardiol; 1992 Apr; 19(5):1071-5. PubMed ID: 1372625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical models.
    Godfrey KR; Tanswell P; Bates RA; Chappell MJ; Madden FN
    Biopharm Drug Dispos; 1998 Mar; 19(2):131-40. PubMed ID: 9533114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.